[2019 international oncology news: A compendium]

Nicolas Magné; Renaud Sabatier; Marie Wislez; Thierry André; Manuel Rodrigues; Laure Hervé; Antoine Thiery-Vuillemin; Nicolas Penel; Carole Bouleuc; Jacques-Olivier Bay

doi:10.1016/j.bulcan.2020.01.010

[2019 international oncology news: A compendium]

Bull Cancer. 2020 Feb;107(2):148-156. doi: 10.1016/j.bulcan.2020.01.010. Epub 2020 Feb 10.

[Article in French]

Authors

Affiliations

¹ Institut de cancérologie Lucien Neuwirth, département universitaire de la recherche et de l'enseignement, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42270 Saint-Priest-en-Jarez cedex, France; Institut de physique nucléaire de Lyon (IPNL), faculté de médecine Lyon-Sud, radiobiologie cellulaire et moléculaire, UMR 5822, 69622 Villeurbanne, France. Electronic address: [email protected].
² Aix-Marseille université, institut Paoli-Calmettes, CRCM - département d'oncologie médicale, Inserm, CNRS, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
³ Hôpital Cochin, service de pneumologie, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France.
⁴ Hôpital Saint-Antoine, Sorbonne université, service d'oncologie médicale, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France.
⁵ DNA repair and uveal melanoma (D.R.U.M.), Inserm U830, équipe labellisée par la Ligue nationale contre le cancer, 75005 Paris, France; PSL research university, institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
⁶ CHRU Jean Minjoz, department of medical oncology, 25030 Besançon cedex, France.
⁷ CHRU Jean Minjoz, department of medical oncology, 25030 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France.
⁸ Centre Oscar Lambret, département de cancérologie générale, 3, rue Frédéric-Combemale, 59000 Lille, France.
⁹ Institut Curie, département de soins de support, 26, rue d'Ulm, 75005 Paris, France.
¹⁰ Centre hospitalier universitaire Giscard d'Estaing, service thérapie cellulaire et hématologie clinique, 58, rue Montalembert, 63000 Clermont Ferrand, France.

PMID: 32057466
DOI: 10.1016/j.bulcan.2020.01.010

Abstract

Over the past years, planet oncology has kept changing and moving forward. Recent results of important clinical trials are challenging our daily practices. With modesty, the Editorial Board of BulletinduCancer has selected some clinical trials they consider as "must-know about" even if they go beyond our medical fields.

Keywords: Breast cancer; Cancers broncho-pulmonaires; Cancers de la prostate; Cancers de primitifs inconnus; Cancers digestifs; Cancers du sein; Cancers gynécologiques; Digestive cancer; Gynaecological cancer; Lung cancer; Palliative care; Prostate cancer; Soins palliatifs; Unknown primary cancer.

Publication types

Review

MeSH terms

Aminopyridines / therapeutic use
Breast Neoplasms / drug therapy
Clinical Trials as Topic*
Digestive System Neoplasms / therapy
Female
Genital Neoplasms, Female / therapy
Humans
Lung Neoplasms / therapy
Male
Molecular Targeted Therapy
Neoplasms / therapy*
Neoplasms, Unknown Primary / therapy
Prostatic Neoplasms / therapy
Purines / therapeutic use

Substances

Aminopyridines
Purines
ribociclib